theMednetRegister

Radiation Oncology

ASTRO 2025   

ASTRO 2025 Annual Meeting

Questions discussed in this category

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?
I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage? This question is part of our...
6 Answers available
How will you select patients with brain metastases for TTFields?
The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient se...
2 Answers available
How do molecular and clinical factors guide personalized selection of HSRT dose fractionation regimens with bevacizumab in recurrent high-grade gliomas?
Multivariate analysis identified HSRT dose fractionation, tumor grade, IDH mutation, and 1p/19q codeletion as significant predictors of PFS- do these ...
2 Answers available
When do you consider using protons for breast cancer?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
4 Answers available
How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available
Do you typically recommend placement of a rectal spacer prior to definitive radiotherapy, regardless of dose/fractionation?
Do the results of GU005 impact your recommendation for placement of a rectal spacer? This question is part of our collaboration with ASTRO 2025 to hi...
2 Answers available
When is the ideal time in the disease course to offer radiotherapy for Dupuytren's disease for the most optimal outcomes?
Do patients still derive significant benefit if radiation is offered outside the proliferative phase?   This question is part of our collaborat...
2 Answers available
Do TTFields work synergistically with SRS for patients with brain metastases?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
3 Answers available
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
3 Answers available
How do you select which patients with H&N primary tumors benefit from proton therapy?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
6 Answers available
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
2 Answers available
Are there any scenarios in which you would offer SBRT as your preferred treatment approach for appropriate candidates with intermediate risk prostate cancer?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available
Would you offer re-irradiation LDRT for someone with osteoarthritis or tendinitis if symptoms recur?
If yes, what time frame would you potentially offer this? If they had complete relief in one joint and partial relief in another after 2 courses, woul...
2 Answers available
When in the treatment of OA do you think it is optimal to offer LDRT?
Many guidelines continue to list LDRT as a non-primary/secondary intervention; do you wait to offer LDRT until after trial of conventional primary int...
1 Answer available
How do you balance short-term efficacy against increased low-grade toxicity and quality-of-life considerations for higher single-fraction regimens in recurrent glioma patients?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
Further radioligand therapy upon disease progression? If proceeding with further RLT, how many cycles may be planned?   This question is part o...
1 Answer available
How do you account for dosimetric contributions from 177Lu-PNT2002 when planning SBRT?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available
Does the choice of radiation modality (3D, IMRT/VMAT, protons) impact the effectiveness of the reduced dose of 20 Gy in DLBCL?
Would you prefer certain modalities if using the lower dose?   This question is part of our collaboration with ASTRO 2025 to highlight impactfu...
1 Answer available
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups?   This question is part of our c...
1 Answer available


Papers discussed in this category

International journal of radiation oncology, biology, physics, 2010-11-01
Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
American journal of clinical oncology, 2016-02
Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.
Radiother Oncol, 2013-01-01
Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.
The New England journal of medicine, 2011-07-14
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
The Lancet. Oncology, 2018-11
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
J Clin Oncol, 2021 Jan 26
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
Int J Radiat Oncol Biol Phys,
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.
The Lancet. Oncology, 2025 May 05
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.
Eur Urol Oncol, 2020 May 22
PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
The Journal of urology, 2015-12
Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
International journal of radiation oncology, biology, physics, 2017-04-01
Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study.
Brachytherapy, 2018
The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation.
The New England journal of medicine, 2013-03-14
Risk of ischemic heart disease in women after radiotherapy for breast cancer.
Breast Cancer Res. Treat., 2020 Apr 03
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
Strahlenther Onkol, 2021 Oct
Low-dose radiotherapy for painful osteoarthritis of the elderly: A multicenter analysis of 970 patients with 1185 treated sites.
International journal of radiation oncology, biology, physics, 2025 Feb 22
Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.
Radiother Oncol, 2020 Apr 01
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
The New England journal of medicine, 2024 Oct 17
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Strahlenther Onkol, 2010 Jan 28
Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years.
Int. J. Radiat. Oncol. Biol. Phys.,
Radiotherapy optimization in early-stage Dupuytren's contracture: first results of a randomized clinical study.
International journal of radiation oncology, biology, physics, 1996 Nov 01
Radiotherapy for prevention of disease progression in early-stage Dupuytren's contracture: initial and long-term results.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997 Jan
[Radiotherapy in the early stage of Dupuytren's disease. The indications, technic and long-term results].
International journal of radiation oncology, biology, physics, 2025 Sep 28
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's disease: Three year secondary analysis data from the Prevention Group of the International DEPART Randomized Trial.
Ann Rheum Dis, 2019 Jan
Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial.
Osteoarthritis and cartilage, 2018 Jul 07
Lack of beneficial effects of low-dose radiation therapy on hand osteoarthritis symptoms and inflammation: a randomised, blinded, sham-controlled trial.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021 Nov 01
ArthroRad trial: multicentric prospective and randomized single-blinded trial on the effect of low-dose radiotherapy for painful osteoarthritis depending on the dose-results after 3 months' follow-up.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023 Oct 10
ArthroRad trial: randomized multicenter single-blinded trial on the effect of low-dose radiotherapy for painful osteoarthritis-final results after 12-month follow-up.
Frontiers in immunology, 2022 Jan 03
Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients.
The British journal of radiology, 2015 May 08
Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.
BMC Cancer, 2020 Jun 1
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Acta neurochirurgica, 2021 Apr 02
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
The New England journal of medicine, 2017-02-02
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
The New England journal of medicine, 2018-07-12
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
JAMA oncology, 2017-12-01
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
JAMA Oncol, 2020 Mar 26
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
Lancet Oncol, 2019 Oct 16
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
N Engl J Med, 2021 Dec 01
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Lancet,
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019 Sep 12
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
Lancet (London, England), 2024 May 16
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
European urology, 2025 Jun 25
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
The Lancet. Oncology, 2023 Sep
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

Related Topics in Radiation Oncology

Copyright © 2025 theMednet
All Rights Reserved.